A calcium-protease activator associated with brain microsomal-insoluble elements

AbstractA factor which markedly activates Ca2+-dependent thiol protease (calpain) is associated with Triton X-100-insoluble materials, presumably structural elements such as cytoskeletons, of bovine brain microsomal fraction. This factor is extracted with 0.6 M KCl, and purified partially by sucrose density gradient centrifugation and hydroxyapatite column chromatography. The factor appears to be a heat-stable protein with an approximate Mr, of 15000. With casein as substrate this factor activates both calpain I and calpain II severalfold up to more than 10- fold without alteration of their affinity to Ca2+. Calmodulin is unable to substitute for this factor. A similar factor is associated with human platelet insoluble materials

Comparison of Geophysical Model Functions for SAR Wind Speed Retrieval in Japanese Coastal Waters

Abstract: This work discusses the accuracies of geophysical model functions (GMFs) for retrieval of sea surface wind speed from satellite-borne Synthetic Aperture Radar (SAR) images in Japanese coastal waters characterized by short fetches and variable atmospheric stability conditions. In situ observations from two validation sites, Hiratsuka and Shirahama, are used for comparison of the retrieved sea surface wind speeds using CMOD (C-band model)4, CMOD_IFR2, CMOD5 and CMOD5.N. Of all the geophysical model functions (GMFs), the latest C-band GMF, CMOD5.N, has the smallest bias and root mean square error at both sites. All of the GMFs exhibit a negative bias in the retrieved wind speed. In order to understand the reason for this bias, all SAR-retrieved wind speeds are separated into two categories: onshore wind (blowing from sea to land) and offshore wind (blowing from land to sea). Only offshore winds were found to exhibit the large negative bias, and short fetches from the coastline may be a possible reason for this. Moreover, it is clarified that in both the unstable and stable conditions, CMOD5.N has atmospheric stability effectiveness, and can keep the same accuracy with CMOD5 in the neutral condition. In short, at the moment, CMOD5.N is thought to be the most promising GM

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension